Evaluation of Humoral Response following SARS-CoV-2 mRNA-Based Vaccination in Liver Transplant Recipients Receiving Tailored Immunosuppressive Therapy DOI Open Access
Tommaso Maria Manzia, Bruno Sensi, Luigi Eduardo Conte

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(21), P. 6913 - 6913

Published: Nov. 3, 2023

Background: The role of tailored immunosuppression (IS) in the development humoral response (HR) to SARS-CoV-2 mRNA-based vaccination liver transplant (LT) recipients is unknown. Methods: This a single-centre prospective study patients who underwent LT between January 2015 and December 2021 have received three doses vaccination. Patients undergoing Tacrolimus-based (TAC-IS) were compared with those Everolimus-based (EVR-IS). receiving TAC-EVR combination divided into two groups based on trough TAC concentrations, i.e., above or below 5 ng/mL. HR (analysed ECLIA) was assessed at 30 135 days after primary outcome presence positive antibody titre (≥0.8 U/mL). Secondary outcomes highly protective (≥142 U/mL), median titre, incidence COVID-19. Results: Sixty-one participants included. Twenty-four (40%) TAC-IS thirty-seven (60%) EVR-IS. At follow-up 116 (range: 89-154) days, there no significant differences (95.8% vs. 94.6%; p = 0.8269), highly-protective (83.3% 81.1%; 0.8231), (2410 [IQ range 350-2500] 1670 380-2500]; 0.9450), COVID-19 (0% 5.4%; 0.5148). High serum creatinine low estimated glomerular filtration rate risk factors for weak absent HR. Conclusions: Three yielded recipients. use EVR-based IS does not appear influence while renal disease factor null

Language: Английский

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper DOI Open Access
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler

et al.

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 77(4), P. 1161 - 1197

Published: July 20, 2022

Language: Английский

Citations

62
Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections DOI Creative Commons
Birte Möhlendick,

Ieva Čiučiulkaitė,

Carina Elsner

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: June 23, 2022

Background Despite the high level of protection against severe COVID-19 provided by currently available vaccines some breakthrough infections occur. Until now, there is no information whether a potential risk infection can be inferred from antibodies after booster vaccination. Methods Levels binding and neutralization capacity first, one six month second, third (booster) vaccination were measured in serum samples 1391 healthcare workers at University Hospital Essen. Demographics, scheme, pre-infection antibody titers compared between individuals with without infections. Results The developing an Omicron was independent sex, body mass index, smoking status or pre-existing conditions. In participants low anti-spike (≤ 2641.0 BAU/ml) weaker 65.9%) for 10-fold increased ( P = 0.001; 95% confidence interval, 2.36 - 47.55). Conclusion Routine testing anti-SARS-CoV-2 IgG surrogate virus quantify vaccine-induced humoral immune response may help to identify subjects who are infection. establishment thresholds SARS-CoV-2 levels identifying “non”-, “low” “high”-responders used as indication re-vaccination.

Language: Английский

Citations

25
COVID-19 Vaccination in Patients with Chronic Liver Disease DOI Creative Commons
Georgios Schinas,

Eleni Polyzou,

Fevronia Mitropetrou

et al.

Viruses, Journal Year: 2022, Volume and Issue: 14(12), P. 2778 - 2778

Published: Dec. 13, 2022

Vaccination against SARS-CoV-2 has become a central public health issue, primarily for vulnerable populations such as individuals with Chronic Liver Disease (CLD). Increased COVID-19-related mortality and disease severity been noted in this subgroup of patients. Severe COVID-19 tends to further deregulate liver function patients chronic failure or cirrhosis even reactivate hepatitis people living HBV HCV. In addition, impaired hepatic leads several limitations possible therapeutic interventions. dysregulation, along the underlying cirrhosis-associated immune dysfunction (CAID), decreased response vaccination that, turn, may result reduced efficacy rates lowered lasting protection. According current guidelines, timely frequent booster shot administration are deemed necessary context. Vaccination-related adverse events mostly mild nature similar those reported general population, whereas incidence injury following is relatively rare. We aimed review available evidence recommendations associated disease, provide insight issues future directions.

Language: Английский

Citations

22
Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response DOI Creative Commons
Vincenzo Giambra,

Annarita Valeria Piazzolla,

Giovanna Cocomazzi

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(8), P. 1281 - 1281

Published: Aug. 8, 2022

Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- T-cell immune response are currently available. Aims: To assess, in comparison healthy controls of the same age gender, both humoral cellular immunoresponses patients after two or three doses mRNA Pfizer-BioNTech vaccine against SARS-CoV-2 investigate clinical features non-response. Material methods: 179 CTP class A 93.3% viral etiology 70.1% cases were longitudinally evaluated starting from day before first dose 4 weeks booster dose. Their antibody responses compared those healthcare workers without co-morbidities. In a subgroup 40 patients, also controls. Results: At d31, d90 d180 BNT162b2 vaccine, detectable IgG was observed 5.9%, 3.9% 7.2% as 0 (p < 0.03). delay B-cell lack prompt registered. significant correlation between titers observed. MELD score > 8 only independent predictor poor d31 = 0.028). Conclusions: Our results suggest that cirrhotic have slower <10% suboptimal vaccination. Rates breakthrough infections comparable cirrhotics The critical inducing

Language: Английский

Citations

17
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes DOI Creative Commons
Luke Baldelli, Thomas Marjot, Eleanor Barnes

et al.

Gut and Liver, Journal Year: 2022, Volume and Issue: 17(1), P. 12 - 23

Published: Dec. 2, 2022

The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions.While severe acute respiratory syndrome 2 (SARS-CoV-2) virus primarily infects system, other organ systems are affected, including liver.Scientific knowledge on role SARS-CoV-2 infection liver injury evolved rapidly, with recent data suggesting specific hepatotropism SARS-CoV-2.Moreover, additional concerns raised in regard long-term damage, related emerging cases post-COVID-19 cholangiopathy chronic cholestasis.Great effort also focused studying how subpopulations medical conditions might be disproportionately impacted by COVID-19.One such population includes individuals (CLD) cirrhosis, an expanding body research indicating these patients being particularly susceptible adverse outcomes.In this review, we provide updated summary current pathogenesis mechanism setting infection, association between health outcomes CLD, unique consequences COVID-19 routine care CLD.(Gut Liver

Language: Английский

Citations

15
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients DOI Creative Commons
Alfredo Papa, Marcello Covino, Sara Sofia De Lucia

et al.

World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(26), P. 4099 - 4119

Published: July 6, 2023

Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, impact COVID-19 on patients pre-existing digestive diseases still needs to be fully elucidated, particularly older population. This review aimed investigate GI tract, liver, and pancreas individuals without previous diseases, a particular focus elderly, highlighting distinctive characteristics observed this Finally, effectiveness adverse events anti-COVID-19 vaccination disorders peculiarities found discussed.

Language: Английский

Citations

7
High vaccination coverage and infection rate result in a robust SARS‐CoV‐2‐specific immunity in the majority of liver cirrhosis and transplant patients: A single‐center cross‐sectional study DOI Creative Commons
P. von der Schulenburg, A. Herting, Aenne Harberts

et al.

United European Gastroenterology Journal, Journal Year: 2024, Volume and Issue: 12(3), P. 339 - 351

Published: Jan. 27, 2024

Abstract Background In the third year of SARS‐CoV‐2 pandemic, little is known about vaccine‐ and infection‐induced immune response in liver transplant recipients (LTR) cirrhosis patients (LCP). Objective This cross‐sectional study assessed vaccination coverage, infection rate, resulting humoral cellular SARS‐CoV‐2‐specific responses a cohort LTR LCP at University Medical Center Hamburg‐Eppendorf, Germany between March May 2023. Methods Clinical laboratory data from 244 consecutive (160 84 LCP) were collected via chart review patient survey. Immune determined standard spike(S)‐ nucleocapsid‐protein serology spike‐specific Interferon‐gamma release assay (IGRA). Results On average, vaccinated 3.7 3.3 times, respectively 59.4% received ≥4 vaccinations. Altogether, 68.1% (109/160) 70.2% (59/84) experienced infection. Most infections occurred during Omicron wave 2022 after an average 3.0 Overall, hospitalization rate was low (<6%) both groups. An 4.3 antigen contacts by and/or resulted seroconversion 98.4%. However, 17.5% (28/160) 8.3% (7/84) demonstrated only anti‐S titers (<1000 AU/ml), 24.6% (16/65) 20.4% (10/59) had negative or IGRA responses. Patients with hybrid immunity (vaccination plus infection) elicited significantly higher compared uninfected same number spike contacts. A total 22.2% refused additional booster Conclusion By spring 2023, high coverage have robust, mostly hybrid, most LCP. vaccinations vaccines covering new variants seem advisable, especially risk factors for severe disease.

Language: Английский

Citations

2
COVID-19 in Individuals with Chronic Liver Diseases DOI Open Access

Konstantina Toutoudaki,

Θεόδωρος Ανδρουτσάκος

Journal of Gastrointestinal and Liver Diseases, Journal Year: 2024, Volume and Issue: 33(1), P. 7 - 10

Published: March 29, 2024

Patients with chronic liver diseases (CLD) were considered to be in peril during the initial stages of Coronavirus disease (Covid-19) pandemic. Progression course pandemic, however indicated that risk severe and mortality differed, based on cause hepatic disease. suffering from Alcoholic or cirrhosis confirmed at an increased by numerous studies, while was not case for HBV affected individuals transplant recipients. The grade fibrosis seemed decisive factor severity Covid-19 infection HCV infected individuals. Results are conflicting patients metabolic- associated steatotic (MASLD) insufficient those autoimmune

Language: Английский

Citations

2
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study DOI Open Access
Amandeep Singh, Arka De, Mini P. Singh

et al.

Digestive Diseases and Sciences, Journal Year: 2022, Volume and Issue: 68(2), P. 676 - 684

Published: Sept. 25, 2022

Language: Английский

Citations

11
Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients DOI
Anand V. Kulkarni, J. Shashidhar,

Sowmya Iyengar

et al.

Vaccine, Journal Year: 2022, Volume and Issue: 40(48), P. 6971 - 6978

Published: Oct. 25, 2022

Language: Английский

Citations

11